{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:03:07Z","timestamp":1767139387059,"version":"build-2238731810"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T00:00:00Z","timestamp":1516060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00108-017-0362-5","type":"journal-article","created":{"date-parts":[[2018,1,16]],"date-time":"2018-01-16T04:17:24Z","timestamp":1516076244000},"page":"288-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Thrombozytenaggregationshemmer bei koronarer, zerebraler und peripherer Makroangiopathie","Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy"],"prefix":"10.1007","volume":"59","author":[{"given":"M.","family":"Halbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,16]]},"reference":[{"key":"362_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx095","author":"V Aboyans","year":"2017","unstructured":"Aboyans V, Ricco JB, Bartelink MEL et\u00a0al (2017) 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesendorsed by: the European stroke organization (ESO)the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European society for vascular surgery (ESVS). Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx095","journal-title":"Eur Heart J"},{"key":"362_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2012.03.050","volume":"60","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Galati A, Xanthopoulou I et al (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a\u00a0pharmacodynamic study. J\u00a0Am Coll Cardiol 60:193\u2013199","journal-title":"J Am Coll Cardiol"},{"key":"362_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antithrombotic Trialists C","year":"2002","unstructured":"Antithrombotic Trialists C (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71\u201386","journal-title":"BMJ"},{"key":"362_CR4","series-title":"JAMA","first-page":"2507","volume-title":"Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a\u00a0systematic review and meta-analysis","author":"A Bellemain-Appaix","year":"2012","unstructured":"Bellemain-Appaix A, O\u2019Connor SA, Silvain J et al (2012) Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a\u00a0systematic review and meta-analysis. JAMA, Bd. 308., S 2507\u20132516"},{"key":"362_CR5","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W et\u00a0al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N\u00a0Engl J Med 354:1706\u20131717","journal-title":"N Engl J Med"},{"key":"362_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijcard.2010.08.035","volume":"150","author":"G Biondi-Zoccai","year":"2011","unstructured":"Biondi-Zoccai G, Lotrionte M, Agostoni P et al (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 150:325\u2013331","journal-title":"Int J Cardiol"},{"key":"362_CR7","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N\u00a0Engl J Med 372:1791\u20131800","journal-title":"N Engl J Med"},{"key":"362_CR8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et\u00a0al (2017) Dual antithrombotic therapy with Dabigatran after PCI in atrial fibrillation. N\u00a0Engl J Med 377:1513\u20131524","journal-title":"N Engl J Med"},{"key":"362_CR9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa042087","volume":"352","author":"FK Chan","year":"2005","unstructured":"Chan FK, Ching JY, Hung LC et\u00a0al (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N\u00a0Engl J Med 352:238\u2013244","journal-title":"N Engl J Med"},{"key":"362_CR10","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CS Committee","year":"1996","unstructured":"Committee CS (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348:1329\u20131339","journal-title":"Lancet"},{"key":"362_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, van Klaveren D, James S et al (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a\u00a0pooled analysis of individual-patient datasets from clinical trials. Lancet 389:1025\u20131034","journal-title":"Lancet"},{"key":"362_CR12","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW et al (2013) Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381:1107\u20131115","journal-title":"Lancet"},{"key":"362_CR13","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J et\u00a0al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N\u00a0Engl J Med 377:1319\u20131330","journal-title":"N Engl J Med"},{"key":"362_CR14","volume-title":"Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke","author":"M Endres","year":"2015","unstructured":"Endres M, Diener H\u2011C, Behnke M, R\u00f6the J (2015) Sekund\u00e4rprophylaxe isch\u00e4mischer Schlaganfall und transitorische isch\u00e4mische Attacke (\n                    http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/030-133l_S3_Sekun%C3%A4rprophylaxe_isch%C3%A4mischer_Schlaganfall_2015-02.pdf\n                    \n                  )"},{"key":"362_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jama.2010.221","volume":"303","author":"FG Fowkes","year":"2010","unstructured":"Fowkes FG, Price JF, Stewart MC et\u00a0al (2010) Aspirin for prevention of cardiovascular events in a\u00a0general population screened for a\u00a0low ankle brachial index: a\u00a0randomized controlled trial. JAMA 303:841\u2013848","journal-title":"JAMA"},{"key":"362_CR16","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C et\u00a0al (2016) Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N\u00a0Engl J Med 375:2423\u20132434","journal-title":"N Engl J Med"},{"key":"362_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","volume":"135","author":"CM Gibson","year":"2017","unstructured":"Gibson CM, Pinto DS, Chi G et al (2017) Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of Rivaroxaban or a\u00a0dose-adjusted oral vitamin K antagonist treatment strategy. Circulation 135:323\u2013333","journal-title":"Circulation"},{"key":"362_CR18","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, Sorensen R, Clausen MT et\u00a0al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170:1433\u20131441","journal-title":"Arch Intern Med"},{"key":"362_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacc.2010.10.029","volume":"57","author":"C Held","year":"2011","unstructured":"Held C, Asenblad N, Bassand JP et\u00a0al (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J\u00a0Am Coll Cardiol 57:672\u2013684","journal-title":"J Am Coll Cardiol"},{"key":"362_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1611688","volume":"376","author":"WR Hiatt","year":"2017","unstructured":"Hiatt WR, Fowkes FG, Heizer G et\u00a0al (2017) Ticagrelor versus Clopidogrel in symptomatic peripheral artery disease. N\u00a0Engl J Med 376:32\u201340","journal-title":"N Engl J Med"},{"key":"362_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx393","journal-title":"Eur Heart J"},{"key":"362_CR22","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S Connolly","year":"2006","unstructured":"Investigators AWGotA, Connolly S, Pogue J et\u00a0al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel trial with Irbesartan for prevention of vascular events (ACTIVE W): a\u00a0randomised controlled trial. Lancet 367:1903\u20131912","journal-title":"Lancet"},{"key":"362_CR23","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S, Budaj A, Aylward P et\u00a0al (2010) Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122:1056\u20131067","journal-title":"Circulation"},{"key":"362_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1603060","volume":"375","author":"SC Johnston","year":"2016","unstructured":"Johnston SC, Amarenco P, Albers GW et\u00a0al (2016) Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N\u00a0Engl J Med 375:35\u201343","journal-title":"N Engl J Med"},{"key":"362_CR25","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et\u00a0al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart\u00a0J 37:2893\u20132962","journal-title":"Eur Heart J"},{"key":"362_CR26","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ et al (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N\u00a0Engl J Med 339:1665\u20131671","journal-title":"N Engl J Med"},{"key":"362_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD et\u00a0al (2012) Rivaroxaban in patients with a\u00a0recent acute coronary syndrome. N\u00a0Engl J Med 366:9\u201319","journal-title":"N Engl J Med"},{"key":"362_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","volume":"373","author":"G Montalescot","year":"2009","unstructured":"Montalescot G, Wiviott SD, Braunwald E et al (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373:723\u2013731","journal-title":"Lancet"},{"key":"362_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa1308075","volume":"369","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N\u00a0Engl J Med 369:999\u20131010","journal-title":"N Engl J Med"},{"key":"362_CR30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","volume":"371","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, van \u2019t Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N\u00a0Engl J Med 371:1016\u20131027","journal-title":"N Engl J Med"},{"key":"362_CR31","doi-asserted-by":"crossref","unstructured":"Sch\u00e4fer A, Arntz HR, Boudriot E, Garlichs C, Hoffmann S, Ince H, Klingenheben T, Weil J, Zugck C, Helms TM, Silber S (2014) Differenzierte antithrombozyt\u00e4re Therapie bei akutem Koronarsyndrom. Dtsch med Wochenschr 139(04):152\u2013158","DOI":"10.1055\/s-0033-1359911"},{"key":"362_CR32","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","volume":"389","author":"EM Ohman","year":"2017","unstructured":"Ohman EM, Roe MT, Steg PG et al (2017) Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a\u00a0double-blind, multicentre, randomised trial. Lancet 389:1799\u20131808","journal-title":"Lancet"},{"key":"362_CR33","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, Hoes AW, Agewall S et\u00a0al (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts)developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart\u00a0J 37:2315\u20132381","journal-title":"Eur Heart J"},{"key":"362_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2016.01.004","volume":"174","author":"TJ Povsic","year":"2016","unstructured":"Povsic TJ, Roe MT, Ohman EM et al (2016) A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study. Am Heart\u00a0J 174:120\u2013128","journal-title":"Am Heart J"},{"key":"362_CR35","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KA et\u00a0al (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N\u00a0Engl J Med 367:1297\u20131309","journal-title":"N Engl J Med"},{"key":"362_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12265-013-9527-3","volume":"7","author":"S Schulz","year":"2014","unstructured":"Schulz S, Angiolillo DJ, Antoniucci D et al (2014) Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy\u2014design and rationale of the intracoronary stenting and antithrombotic regimen: rapid early action for coronary treatment (ISAR-REACT) 5 trial. J\u00a0Cardiovasc Transl Res 7:91\u2013100","journal-title":"J Cardiovasc Transl Res"},{"key":"362_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/2048872614534078","volume":"3","author":"S Servi de","year":"2014","unstructured":"Servi S de, Goedicke J, Schirmer A et al (2014) Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial. Eur Heart J Acute Cardiovasc Care 3:363\u2013372","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"362_CR38","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a\u00a0randomised, open-label, multicentre trial. Lancet 390:1747\u20131757","journal-title":"Lancet"},{"key":"362_CR39","doi-asserted-by":"publisher","first-page":"912","DOI":"10.4330\/wjc.v7.i12.912","volume":"7","author":"S Spiliopoulos","year":"2015","unstructured":"Spiliopoulos S, Pastromas G (2015) Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: mechanisms, evaluation and clinical implications. World J Cardiol 7:912\u2013921","journal-title":"World J Cardiol"},{"key":"362_CR40","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Task Force M, Montalescot G, Sechtem U et\u00a0al (2013) 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart\u00a0J 34:2949\u20133003","journal-title":"Eur Heart J"},{"key":"362_CR41","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"D Trenk","year":"2012","unstructured":"Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on Clopidogrel to guide alternative therapy with Prasugrel) study. J\u00a0Am Coll Cardiol 59:2159\u20132164","journal-title":"J Am Coll Cardiol"},{"key":"362_CR42","first-page":"390","volume":"37","author":"JA Udell","year":"2016","unstructured":"Udell JA, Bonaca MP, Collet JP et al (2016) Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a\u00a0collaborative meta-analysis of randomized trials. Eur Heart\u00a0J 37:390\u2013399","journal-title":"Eur Heart J"},{"key":"362_CR43","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A et al (2015) Polymer-free drug-coated coronary stents in patients at high bleeding risk. N\u00a0Engl J Med 373:2038\u20132047","journal-title":"N Engl J Med"},{"key":"362_CR44","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","volume":"65","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Patialiakas A, Thury A et al (2015) Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J\u00a0Am Coll Cardiol 65:805\u2013815","journal-title":"J Am Coll Cardiol"},{"key":"362_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA et al (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart\u00a0J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"362_CR46","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et\u00a0al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N\u00a0Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"362_CR47","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH et\u00a0al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N\u00a0Engl J Med 357:2001\u20132015","journal-title":"N Engl J Med"},{"key":"362_CR48","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"SD Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, Angiolillo DJ et\u00a0al (2008) Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: thrombolysis in myocardial infarction 38. Circulation 118:1626\u20131636","journal-title":"Circulation"}],"updated-by":[{"DOI":"10.1007\/s00108-018-0461-y","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000}}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-017-0362-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0362-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-017-0362-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T19:03:44Z","timestamp":1547579024000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-017-0362-5"}},"subtitle":["Was, wann, wie lange?","What, when and how long?"],"short-title":[],"issued":{"date-parts":[[2018,1,16]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1007\/s00108-017-0362-5","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,16]]},"assertion":[{"value":"16 January 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum zu:Internist 2018\n                      \n                      In der gedruckten und in der zun\u00e4chst online ver\u00f6ffentlichten Fassung dieses Beitrags ist ein Fehler in der Darreichungsempfehlung zu Ticagrelor-Schmelztabletten im Abschnitt \u201eBeginn der dualen Pl\u00e4ttchenhemmung\u201c aufgetreten. Die \u2026","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Halbach hat Vortragshonorare von AstraZeneca, Bayer, BMS\/Pfizer und Daiichi Sankyo erhalten. S.\u00a0Baldus hat Vortragshonorare von AstraZeneca, Bayer, BMS\/Pfizer und Daiichi Sankyo erhalten.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}